off-licence manner). The pivotal randomised controlled trials (RCTs) that led to the approval of these agents only included one eye per patient as a means of preventing bias due to correlation between eyes. [1, 2] This is a necessary step in RCTs, as not accounting for this effect can lead to overestimation of precision and a falsely low p-value. [3] However, this systematically excludes eyes of patients who subsequently develop nAMD in their fellow eye. From a patient's perspective however, vision-related quality of life does not only depend on the course of visual acuity (VA) in the first treated eye. [4] Legal requirements largely focus on the VA of the better seeing eye. For example, in the United Kingdom, the VA standard for driving is 20/40 and the limit for obtaining a certificate of severe sight impairment is 20/400 (tested binocularly or in the better seeing eye). [5, 6] Additionally, patients with bilateral nAMD have functional impairments that lead to a high socioeconomic burden. [7] [8] [9] Data on treatment of fellow eyes, specifically sequentially treated fellow eyes, have been reported in small retrospective studies and in one large multicentre electronic medical record (EMR) report. [10] [11] [12] [13] These studies concluded that fellow eyes commenced treatment with a higher baseline VA in comparison to the first treated eyes. In addition, they had a smaller gain in VA over time due to the relatively higher baseline VA, i.e., a ceiling effect.
However, these studies do not account for non-sequentially treated fellow eyes, i.e., eyes starting treatment for nAMD in fellow eyes with an untreated first eye (e.g. due to development of nAMD in the first eye before anti-VEGF approval or late presentation at first eye involvement). Given that involvement of the fellow eye has a substantial impact on vision- Diabetic Retinopathy Study (ETDRS) letters, the lack of requirement to merge data from different sites and systems, the standardised treatment scheme following national guidelines, and the ability to directly access the raw imaging data from each patient visit. [15, 16] The aim of this study was to analyse baseline characteristics and VA outcomes of fellow eyes (sequentially and non-sequentially treated) undergoing anti-VEGF therapy for nAMD, as well as the timelines for fellow eye involvement. We compare fellow eye outcomes to those of the respective first eyes of sequentially treated fellow eyes.
METHODS

Study Population:
Data for this retrospective, comparative, non-randomised cohort study was extracted from the scans. An exemplar case for each group is shown in Figure 1 .
Approval for data collection and analysis was obtained from the Institutional Review
Board at Moorfields (ROAD17/031) and adhered to the tenets set forth in the Declaration of Helsinki.
Efforts to Minimise Bias:
To minimise survival bias/loss to follow-up (LTFU), all first and fellow eyes that did not complete follow-up were manually validated for the correct date of first injection. Outcome Measures:
The primary outcomes were analogous to the pivotal RCTs, and as recommended by The
International Consortium for Health Outcomes Measurement (ICHOM) AMD study group: 
Statistical Analysis:
The data were analysed using the statistics software R (https://www.r-project.org/; provided in the public domain by R Core team 2017 R Foundation for Statistical Computing, Vienna, Austria). The ggplot2 package was used for plots. The eye was defined as unit of analysis. Descriptive statistics included mean +/-95% confidence interval (CI), and median, where appropriate. Differences between groups were evaluated using Mann Whitney U test and Pearson Chi-Square. A p value of < 0.05 was interpreted as statistically significant.
Data Sharing Statement:
De-personalised data as well as the code used for analysis for this study will be openly available from the Dryad Digital Repository https://doi.org/.... This should allow both for independent replication of our results as well as additional novel analyses. Depersonalisation was carried out through hash function anonymisation of patient identification numbers, and replacement of appointment dates with follow-up days to baseline. Approval of adequate depersonalisation was obtained by Moorfields Information Governance.
RESULTS
Baseline Characteristics:
Of the 2710 patients starting treatment in one eye, 1180 (44%) developed fellow eye involvement, 413 (15%) were identified as non-sequentially treated fellow eye involvement, whereas 1117 (41%) were singular/unilateral eyes. Supplementary sFigure 1 shows the flow chart for eyes through the analysis. Mean baseline VA was 54±16 letters for first eyes and 62±13 letters for fellow eyes in sequentially treated patients, and 52±16 letters for nonsequentially treated fellow eyes ( Table 1 : Baseline visual acuity and visual acuity outcomes of first and fellow eyes in sequential treatment fellow eye involvement, and non-sequentially treated fellow eyes.
Visual Acuity Outcomes:
At one year, mean gain in VA was 5.2±15 letters for first eyes, 2.5±12 letters for sequentially treated fellow eyes, and 4.1±15 letters for non-sequentially treated fellow eyes (Table 1) . At two years, mean gain in VA was 5.6±15 letters for first eyes and 0.65±14 letters for fellow eyes in sequentially treated patients, and 3.6±18 letters for non-sequentially treated fellow eyes.
Fellow eyes showed a significantly lower gain in VA than first eyes and non-sequentially treated fellow eyes at one and two years (p <0.001). However, percentage of eyes with good vision (VA≥70 letters/>20/40) at presentation was 42%,double that of first or non-sequential fellow eyes (p<0.001) and stayed at 46% at two years, significantly higher than both other groups (p≤0.001). VA and change in VA over time is shown in Figure 2 . Percentages of eyes gaining vision (change in VA Table 1 and 
Time to Involvement of Second Eye:
Median time interval between involvement of first and fellow eye in sequential involvement was 71 weeks (interquartile range: 27-147 weeks). Chance of involvement of fellow eye involvement for eyes starting treatment in one eye 21% (486 eyes) at one year and 32% (742 eyes) at two years, and it was dependent on age at presentation of the first eye: At two years, the risk of fellow eye involvement was 20% for patients younger than 60 years and 40% for patients in their eighties. Survival analysis of fellow-eye involvement is shown in Figure 4 .
Injection Frequency:
Mean number of injections was 8 in all groups at one year and 13 at two years with no significant differences between the groups (Table 1 ).
DISCUSSION
Our study shows that fellow eye involvement of nAMD affects 20 to 40% over a two-year period, depending on age at presentation of the first eye, and that there is a significant difference in both baseline VA and VA outcomes depending on characteristics of the first eye.
Fellow eye involvement in nAMD is very common, reaching 20-40% depending on age at presentation after two years in our cohort. This rate falls within the range reported in the
Comparison of AMD Treatments Trials (20.6% at two years) and other studies. [12, 13, [23] [24] [25] With demographic ageing, sight loss and blindness is predicted to increase by 2. In sequential treatment, fellow eyes have a higher baseline VA and maintain good vision over two years of treatment despite the absence of an initial gain in VA comparable to first eyes. This ceiling effect has been well-described and implies a rationale for earliest possible detection and treatment of neovascular changes in AMD. [13, 16] Example A ( Figure   1 ) reflects this fellow eye advantage, in which neovascular AMD in the fellow eye was detected pre-symptomatically and treatment was started immediately. Patients might profit from the routinely performed bilateral OCT imaging at every visit, be more vigilant of VA changes in their fellow eye while undergoing treatment for the first eye, and profit from the already in-place pathway to access treatment for the fellow eye quickly. This effect has led to a discussion about strategies for early detection of nAMD and optimal interval of monitoring of AMD patients. [12, 13, 26] Specifically analysis of imaging biomarkers, possibly aided by artificial intelligence, might prove to be key in risk stratification of fellow eye involvement. [24, 27, 28] Our study demonstrates that non-sequentially treated fellow eyes do not share the typical fellow eye characteristics. They start treatment with a relatively low baseline VA and their gain in VA is higher, very similar to first eyes of sequentially treated patients.
Explanations for this could be that patients with non-treatable advanced neovascular disease in the first eye are not regularly monitored or that there is systematic delay in access to treatment. This is supported by the existing lack of awareness of AMD and evidence of substantial delay from symptoms to treatment in the UK AMD care pathways. [29] Interestingly, in this cohort of patients, vision loss secondary to macular scarring in the first eye does not appear to result in increased vigilance that could lead to early detection of fellow eye involvement. One might argue that scarring in the first eye implies more aggressive disease causing worse VA at presentation of fellow eyes, but the similar VA gain over time to first eyes in our cohort does not support this theory. To our knowledge, the findings on non-sequential fellow eye involvement have not been reported before and highlight the arguably most vulnerable cohort of patients in which vision loss in their fellow and better or functionally only seeing eye will lead to significant visual impairment and socioeconomic burden. [7, 8] The 
VA -visual acuity
Figure 4
Survival probability for fellow eye involvement over time (weeks).
